Histone Deacetylase Inhibitors Facilitate Dihydroartemisinin-Induced Apoptosis in Liver Cancer In Vitro and In Vivo

Interaction between ZBP-89 and p53 mutants and its contribution to effects of HDACi on hepatocellular carcinoma

(2012) Chris Z.Y. Zhang et al.   CELL CYCLE

Hepatocellular Carcinoma

(2011) Nuh N. Rahbari et al.   ANNALS OF SURGERY

Trichostatin A sensitizes HBx-expressing liver cancer cells to etoposide treatment

(2011) Chris Z. Y. Zhang et al.   APOPTOSIS

Increased apoptotic efficacy of lonidamine plus arsenic trioxide combination in human leukemia cells. Reactive oxygen species generation and defensive protein kinase (MEK/ERK, Akt/mTOR) modulation

(2011) Eva Calviño et al.   BIOCHEMICAL PHARMACOLOGY

A phase II study of the histone deacetylase inhibitor vorinostat combined with tamoxifen for the treatment of patients with hormone therapy-resistant breast cancer

(2011) P N Munster et al.   BRITISH JOURNAL OF CANCER

Global cancer statistics

(2011) Ahmedin Jemal et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Combining Histone Deacetylase Inhibitor Vorinostat with Aurora Kinase Inhibitors Enhances Lymphoma Cell Killing with Repression of c-Myc, hTERT, and microRNA Levels

(2011) L. Kretzner et al.   CANCER RESEARCH

SAHA shows preferential cytotoxicity in mutant p53 cancer cells by destabilizing mutant p53 through inhibition of the HDAC6-Hsp90 chaperone axis

(2011) D Li et al.   CELL DEATH AND DIFFERENTIATION

Ran Is a Potential Therapeutic Target for Cancer Cells with Molecular Changes Associated with Activation of the PI3K/Akt/mTORC1 and Ras/MEK/ERK Pathways

(2011) H.-F. Yuen et al.   CLINICAL CANCER RESEARCH

HDAC Inhibitors Potentiate the Activity of the BCR/ABL Kinase Inhibitor KW-2449 in Imatinib-Sensitive or -Resistant BCR/ABL+ Leukemia Cells In Vitro and In Vivo

(2011) T. Nguyen et al.   CLINICAL CANCER RESEARCH

Epidermal growth factor regulates Mcl-1 expression through the MAPK-Elk-1 signalling pathway contributing to cell survival in breast cancer

(2011) E P Booy et al.   ONCOGENE

Human cytomegalovirus activation of ERK and myeloid cell leukemia-1 protein correlates with survival of latently infected cells

(2011) M. B. Reeves et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Dihydroartemisinin accelerates c-MYC oncoprotein degradation and induces apoptosis in c-MYC-overexpressing tumor cells

(2010) Jin-Jian Lu et al.   BIOCHEMICAL PHARMACOLOGY

CG0006, a novel histone deacetylase inhibitor, induces breast cancer cell death via histone-acetylation and chaperone-disrupting pathways independent of ER status

(2010) Hyun Mi Kim et al.   BREAST CANCER RESEARCH AND TREATMENT

The polycomb group protein BMI1 is a transcriptional target of HDAC inhibitors

(2010) Prashant V. Bommi et al.   CELL CYCLE

Potential of immunotherapy for hepatocellular carcinoma

(2010) Ekaterina Breous et al.   JOURNAL OF HEPATOLOGY

Identification of Tumor and Invasion Suppressor Gene Modulators in Bladder Cancer by Different Classes of Histone Deacetylase Inhibitors Using Reverse Phase Protein Arrays

(2010) Justin J. Gould et al.   JOURNAL OF UROLOGY

Transarterial Chemoembolization, Transarterial Chemotherapy, and Intra-arterial Chemotherapy for Hepatocellular Carcinoma Treatment

(2010) Emmanuel A. Tsochatzis et al.   SEMINARS IN ONCOLOGY

Phase II, two-stage, single-arm trial of the histone deacetylase inhibitor (HDACi) romidepsin in metastatic castration-resistant prostate cancer (CRPC)

(2009) L. R. Molife et al.   ANNALS OF ONCOLOGY

EPOX Inhibits Angiogenesis by Degradation of Mcl-1 through ERK Inactivation

(2009) H.-L. Sun et al.   CLINICAL CANCER RESEARCH

Clinical Studies of Histone Deacetylase Inhibitors

(2009) H. M. Prince et al.   CLINICAL CANCER RESEARCH

Time trends in incidence and prognosis of primary liver cancer and liver metastases of unknown origin in a Danish region, 1985–2004

(2009) Rune Erichsen et al.   EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY

Histone deacetylase inhibitors: Potential in cancer therapy

(2009) P.A. Marks et al.   JOURNAL OF CELLULAR BIOCHEMISTRY

Histone Deacetylase Inhibitors in Cancer Therapy

(2009) Andrew A. Lane et al.   JOURNAL OF CLINICAL ONCOLOGY

trans-Resveratrol inhibits H2O2-induced adenocarcinoma gastric cells proliferation via inactivation of MEK1/2-ERK1/2-c-Jun signalling axis

(2008) Katia Aquilano et al.   BIOCHEMICAL PHARMACOLOGY

Evaluation of the In vitro and In vivo Antitumor Activity of Histone Deacetylase Inhibitors for the Therapy of Retinoblastoma

(2008) C. L. Dalgard et al.   CLINICAL CANCER RESEARCH

Artemisinin Blocks Prostate Cancer Growth and Cell Cycle Progression by Disrupting Sp1 Interactions with the Cyclin-dependent Kinase-4 (CDK4) Promoter and Inhibiting CDK4 Gene Expression

(2008) Jamin A. Willoughby et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Dihydroartemisinin induces apoptosis and sensitizes human ovarian cancer cells to carboplatin therapy

(2008) Tao Chen et al.   JOURNAL OF CELLULAR AND MOLECULAR MEDICINE

Role of histone deacetylase inhibitor-induced reactive oxygen species and DNA damage in LAQ-824/fludarabine antileukemic interactions

(2008) Roberto R. Rosato et al.   MOLECULAR CANCER THERAPEUTICS